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ABSTRACT The signaling pathways associated with es-
trogen-induced proliferation of epithelial cells in the repro-
ductive tract have not been defined. To identify receptor
tyrosine kinases that are activated in vivo by 17g3-estradiol
(E2), uteri from ovariectomized mice were examined for
enhanced tyrosine phosphorylation of various receptors and
a receptor substrate following treatment with this hormone.
Within 4 hr after hormone exposure, extracts showed in-
creased phosphotyrosine (P-Tyr) immunoreactivity at several
bands, including 170- and 180-kDa; these bands were still
apparent at 24 hr after E2. Analysis of immunoprecipitates
from uterine extracts revealed that E2 enhanced tyrosine
phosphorylation of the insulin-like growth factor-1 receptor
(IGF-1R) and insulin receptor substrate-1 (IRS-1) by 6 hr.
Comparison of supernatants from IRS-1 and control rabbit
IgG immunoprecipitates indicated that the 170-kDa P-Tyr
band in extracts was equivalent to IRS-1. The receptors for
epidermal growth factor, platelet-derived growth factor, and
basic fibroblast growth factor did not exhibit an E2-induced
increase in P-Tyr content. The nonestrogenic steroid hor-
mones examined did not stimulate the P-Tyr content of
IGF-1R or IRS-1. Immunolocalization of P-Tyr and IRS-1
revealed strong reactivity in the epithelial layer of the uterus
from E2-treated mice, suggesting that the majority of P-Tyr
bands observed in immunoblots originate in the epithelium.
Since hormonal activation of IRS-1 is epithelial, estrogen-
specific, and initiated before maximal DNA synthesis occurs
following treatment with hormone, this protein, as part of the
IGF-1R pathway, may be important in mediating estrogen-
stimulated proliferation in the uterus.
One of the major actions of estrogens in target tissues is the
stimulation of cellular proliferation. The rodent uterus has
served as an experimental model for evaluating steroid hor-
mone action. In the adult ovariectomized rodent, the prolif-
erative response to 17,B-estradiol (E2) occurs mostly in the
luminal and glandular epithelial cells (1, 2). It is postulated that
steroid hormone-enhanced uterine growth is mediated by
locally derived polypeptide growth factors (reviewed in refs. 3
and 4). Receptors for various growth factors, including epi-
dermal growth factor (EGF)/transforming growth factor a,
platelet-derived growth factor (PDGF), and insulin-like
growth factor-1 (IGF-1) are present in various cell types of the
uterus, including the epithelium (5-8). A regulatory pathway
for cell growth is apparently coupled to some receptors, since
growth factors, such as EGF, can exert potent mitogenic
effects on uterine epithelial cells, in vitro (9) and in vivo (10).
Previous studies have shown E2-stimulation of various growth
factor transcripts or immunoreactivity in the rodent uterus (6,
11-13), which suggests that growth factor bioavailability is a
rate-limiting event in hormonal control of uterine growth. It is
not known whether enhanced level of transcript and immu-
noreactivity for a growth factor signifies activation of the
corresponding signaling pathway, or, furthermore, whether
these findings reflect the requirement for multiple growth
factor pathways to mediate estrogen action.
Ligand-induced tyrosine phosphorylation of the cognate
receptor is an important event in the regulation of many
growth factor signaling pathways. Tyrosine autophosphoryla-
tion of some growth factor receptors, such as the EGF receptor
(EGFR), occurs mainly at sites located outside the tyrosine
kinase domain (14). These sites are important for the selective
recruitment of downstream signaling molecules (reviewed in
ref. 15). Unlike the EGFR, tyrosine-phosphorylated IGF-1/
insulin receptors associate poorly with SH2-containing pro-
teins. Instead, the insulin and IGF-1 receptor kinases phos-
phorylate the insulin receptor substrate-1 (IRS-1) on multiple
tyrosine residues; this protein serves to couple these receptors
to SH2-signaling proteins (reviewed in ref. 16).
To identify those growth factor pathways that are actually
stimulated in uteri of ovariectomized mice as a result of
estrogen action, this study examined various receptors and a
receptor substrate for increased phosphotyrosine (P-Tyr) con-
tent following hormone exposure. Immunolocalization was
used to determine specific uterine cell types that contain
components of the activated growth factor receptor pathway.
Identification of sex steroid-induced signaling pathways that
are associated with proliferation of target tissues may provide
insight into biochemical factors that may be implicated in
cancer risk and better rationales for interrupting the develop-
ment or progression of tumors that originate in these tissues.
EXPERIMENTAL PROCEDURES
Materials. Estradiol, progesterone, dexamethasone, and
5a-dihydrotestosterone were from Sigma. EGF was purchased
from Collaborative Biomedical Products (Bedford, MA). Pro-
tein A-Sepharose was from Pharmacia. The Xcell II mini-cell
for SDS/PAGE and the blot module for Western transfer were
from NOVEX (San Diego). Prestained Mr markers were from
Bio-Rad, and the polyvinylidene fluoride membrane was from
Abbreviations: E2, 1713-estradiol; EGF, epidermal growth factor;
IGF-1, insulin-like growth factor-1; PDGF, platelet-derived growth
factor; EGFR, EGF receptor; IRS-1, insulin receptor substrate-1;
P-Tyr, phosphotyrosine; IGF-1R, IGF-1 receptor; PDGFR, PDGF
receptor.
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NOVEX or Millipore (Immobilon-P). Enhanced chemilumi-
nescence reagents were obtained from Amersham.
Antibodies. Horseradish peroxidase-conjugated anti-
phosphotyrosine monoclonal antibody was obtained from ICN
(PY20). A polyclonal antibody against P-Tyr-containing pro-
teins was purchased from Transduction Laboratories (Lexing-
ton, KY). A rabbit polyclonal antiserum was raised against a
peptide corresponding to the extreme C-terminal region (res-
idues 1157-1186) of the rat EGFR (17), as described (18), and
was affinity-purified. Polyclonal antibodies against the human
IGF-1 receptor (IGF-1R, ,3-subunit) and the human fibroblast
growth factor type 2 receptor were purchased from Santa Cruz
Biotechnology. Antisera against the a-subunit of the human
PDGF receptor (PDGFR), the murine PDGFR a-subunit and
the human PDGFR 1-subunit were obtained from Upstate
Biotechnology (Lake Placid, NY). Anti-rat IRS-1 antibody was
purchased from Upstate Biotechnology. Horseradish peroxi-
dase-conjugated donkey anti-rabbit IgG was from Amersham;
rabbit IgG was obtained from Vector Laboratories.
Animals, Treatments, and Preparation of Tissue Extracts.
Procedures with experimental animals followed the guidelines
of the National Institute of Environmental Health Sciences
Animal Care and Use Committee. CD-1 mice (Charles River
Laboratories) were ovariectomized at 76-82 days of age and
were treated at 12-48 days after castration. Each mouse was
injected s.c. with 1 jig E2 in 0.1 ml PBS/1% ethanol, and
uterine or liver tissue collected at various times after treat-
ment; controls received only the vehicle. For hormone spec-
ificity experiments, CD-1 castrates were injected s.c. with 1 jig
E2, 10 jig dexamethasone, 10 ,ug 5a-dihydrotestosterone, 100
,ug progesterone, or vehicle (50 ,u DMSO/4% ethanol); uteri
were collected at 6 hr following treatment with hormones.
Tissue extracts were prepared as described (19) with the
following modifications: tissues were disrupted at 4°C in buffer
A [1% Triton X-100/2 mM EDTA/2 mM EGTA/1 mM
Na3VO4/20 mM NaF/50 ,tM Na2MoO4/20 jug/ml aproti-
nin/20 ,tg/ml leupeptin/15 ,uM (4-amidinophenyl)-methane-
sulfonyl fluoride in 20 mM Hepes, pH 7.4] with three 10-sec
bursts of a Brinkmann polytron at the highest setting. A
constant volume (600 ,ul) of buffer A was used to homogenize
each uterus. A section of liver was disrupted in buffer A on a
7.5% wet weight/volume basis. After centrifugation at
21,000 x g for 1 min, aliquots of the uterine (100-250 ,ug
protein) and liver (300 ,tg protein) extracts were boiled in
Laemmli sample buffer for 5 min. An equivalent volume (15
,tl) of each extract was evaluated by Western blot analysis as
detailed below. Protein concentrations were determined by the
Pierce BCA Protein Assay.
Immunoprecipitation and Western Blot Analysis. Addi-
tional aliquots of the uterine (300-600 ,tg protein) and liver
(750 ,ug protein) tissue extracts were added to buffer B (150
mM NaCl/5 mM EDTA/0.5% Triton X-100 in 50mM Tris, pH
8.5) and incubated with specific antibody, antiserum or control
rabbit IgG followed by the addition of protein A-Sepharose.
Immunoprecipitates were washed three times with buffer B
and, along with corresponding supernatants, were boiled in
Laemmli sample buffer for 5 min. Proteins were resolved by
SDS/8.0% PAGE and transferred to polyvinylidene fluoride
membrane. The membrane was blocked with TBS/0.1%
Tween 20/5% bovine albumin and probed with the appropri-
ate antibodies. Immunoreactive proteins were detected using
enhanced chemiluminescence.
Immunohistochemical Localization. Ovariectomized mice
were injected s.c. with E2 (1 ,ug) or vehicle (0.1 ml PBS/1%
ethanol). At 6 hr following treatments, uteri were perfusion-
fixed with freshly prepared 4% paraformaldehyde in 0.1 M
sodium phosphate buffer (pH 7.4) (20). Immunolocalization of
P-Tyr and IRS-1 was determined on trypsin-treated paraffin
sections by the double peroxidase-antiperoxidase technique
(21). The anti-P-Tyr antibody was from Transduction Labo-
ratories (catalog no. P11230). Substitution of rabbit IgG for the
primary antibodies served as the control.
RESULTS
Estradiol Stimulates Tyrosine Phosphorylation of Uterine
and Liver Proteins. To evaluate estrogen-induced phosphor-
ylation of uterine and liver proteins, tissue extracts prepared at
various times after treatment with E2 were evaluated by
immunoblotting with anti-P-Tyr antibody. Within 4 hr, uterine
extracts from hormone-treated animals revealed an increase in
P-Tyr immunoreactivity at 76-, 170-, and 180-kDa; these bands
were still apparent at 24 hr after E2 treatment (Fig. 1). A
cluster of phosphorylated bands at 120-130 kDa that was
observed in untreated animals intensified as a result of hor-
mone treatment (Fig. 1). Immunoblots of extracts from livers
of these animals showed an increase in P-Tyr immunoreactiv-
ity at 76 kDa by 4 hr after E2 exposure; this band was not
apparent at 24 hr after hormone exposure (data not shown).
Tyrosine Phosphorylation of Uterine IGF-1R. To identify
one or more of the uterine proteins that exhibited an increase
in tyrosine phosphorylation as a result of treatment with E2,
immunoprecipitates of various known receptor tyrosine ki-
nases were evaluated with anti-P-Tyr antibody. Analysis of
immunoprecipitates of the IGF-1R (13-subunit) revealed en-
hanced phosphorylation at 110-kDa in uterine extracts ob-
tained 6 hr after E2 treatment (Fig. 2A). In contrast to the
IGF-1R, the EGFR detected in uterine extracts did not exhibit
a hormone-dependent increase in P-Tyr content at 6 hr
following estrogen exposure (Fig. 2B). The immunoblots
probed with receptor-specific antibodies revealed that recep-
tor protein levels were not significantly altered following
treatment with E2 within the time period studied (Fig. 2A and
B). Evaluation of the immunoprecipitation supernatants
showed that the quantitative removal of each receptor prior to
immunoblotting with anti-P-Tyr antibody did not reduce the
levels of the E2-stimulated P-Tyr bands at 120 to 130-, 170-,
and 180-kDa (Fig. 2 A and B). Incubating the extract from
estrogen- or vehicle-treated (6 hr) mice with antiserum or
antibody specific to either the PDGFR (a- and 13- subunits) or
fibroblast growth factor type 2 receptor also resulted in
precipitates that did not show a change in P-Tyr content (data
not shown). Further examination of EGFR, PDGFR, and
fibroblast growth factor type 2 receptor immunoprecipitates
obtained from uterine extracts at 2 and 12 hr after treatment
with E2 also showed no change in phosphorylation (data not
shown).
To confirm that our methods can detect modulation of
receptor phosphorylation in uteri of mature mice, we tested
the capacity for EGF to stimulate tyrosine phosphorylation of
uterine EGFR in vivo. Immunoblots of the EGFR immuno-
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FIG. 1. Tyrosine phosphorylation in uterine extracts from ovari-
ectomized CD-1 mice at various times after treatment with 1 ,g E2.
Immunoblots (IB) were evaluated with antibody to phosphotyrosine
(P-Tyr). MW, molecular weight markers.
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precipitates showed increased P-Tyr content at a 170-kDa
band as a result of treatment with EGF in the absence of E2
exposure (Fig. 2C). Estradiol apparently enhanced EGF-
induced phosphorylation of the EGFR (Fig. 2C). Though
uterine EGFR protein levels in the immature rat (22) and
ovariectomized, mature mouse (this study, data not shown)
were elevated at 12 hr after E2 exposure, the increase in EGFR
levels at 6 hr after treatment with E2 was negligible compared
with that of controls, indicating that differences in receptor
content at 6 hr after hormone exposure do not account for the
enhanced phosphorylation of the EGFR following treatment
with EGF. This effect may be due to increased uterine vascular
permeability following treatment with E2, which allows for
greater influx of plasma proteins, including exogenously ad-
ministered EGF, into the uterine tissue.
Estradiol Enhances the P-Tyr Content of Uterine IRS-1.
Activation of the IGF-1R causes rapid stimulation of tyrosine
phosphorylation of -the 165- to 180-kDa IRS-1 (23). Since
phosphorylation of the uterine IGF-lR (3-subunit was induced
by E2, we examined whether phosphorylation of IRS-1 was
also estrogen-dependent. IRS-1 immunoprecipitates from
uterine extracts revealed an increase in tyrosine phosphory-
lation of this protein in E2-treated mice when compared with
that from controls (Fig. 3). This hormone-induced increase in
phosphorylation was associated with a slightly decreased mo-
bility on SDS/PAGE as compared with IRS-1 in controls (Fig.
3). To determine whether the 170- or 180-kDa P-Tyr band in
uterine extracts has IRS-1 immunoreactivity, the extracts from
hormone- or vehicle-treated animals were incubated with
anti-IRS-1 antibody or control rabbit IgG. After immunopre-
cipitation with anti-IRS-1 antibody, examination of the clari-
fied supernatants showed a negligible increase in the P-Tyr
immunoreactivity of the 170-kDa band; the P-Tyr level of this
band was markedly increased in supernatants collected after
immunoprecipitation with rabbit IgG (Fig. 3).
Time-Dependent, Uterine-, and Hormone-Specific Stimula-
tion of Tyrosine Phosphorylation of the IGF-1R and IRS-1 by
E2. A coordinated increase in tyrosine phosphorylation of the
IGF-1R and IRS-1 in the uterus was observed by 6 hr and was
still apparent at 30 hr after E2 administration (Fig. 4A and B).
Estradiol did not increase tyrosine phosphorylation of liver
IRS-1 C IRS-1
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FIG. 2. Estradiol stimulates tyrosine phosphorylation of uterine
IGF-1R. Uterine extracts were collected from CD-1 castrates 6 hr
following exposure of 1 ,tg E2 (+) or vehicle (-). Aliquots of extracts
were incubated with specific antibody to the (A) IGF-1R or (B)
EGFR. Immunoprecipitates (IP) and IP supernatants (SUP) were
evaluated by immunoblots (IB) with specific antibody to phosphoty-
rosine (P-Tyr) or to each receptor. The arrow denotes the (3-subunit
of the IGF-1R (110 kDa). (C) Six hours following treatment with E2
or PBS vehicle, mice were injected with EGF (100 ,ug) or vehicle (100
,lI PBS) and uteri were collected 5 min later. EGFR IP were evaluated
with P-Tyr antibody. MW, molecular weight markers.
IB: P-Tyr IRS-1
FIG. 3. Tyrosine phosphorylation of uterine IRS-1 is stimulated by
E2. Uterine extracts were obtained from ovariectomized mice 6 hr
after treatment with 1 ,ug E2 (+) or vehicle (-). Aliquots of extracts
were incubated with anti-IRS-1 antibody or control rabbit IgG (C).
Immunoprecipitates (IP) and IP supernatants (SUP) were examined
by immunoblots (IB) with antibody to phosphotyrosine (P-Tyr) or
IRS-1. The bracket denotes IRS-1, which decreases in mobility (160-
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FIG. 4. Time-dependent stimulation of tyrosine phosphorylation
of (A) IGF-1R and (B) IRS-1 by E2. At various times following
exposure to E2 (1 ,g), uterine extracts were obtained from ovariec-
tomized mice. Immunoblots (IB) of the IGF-1R (3-subunit) or IRS-1
immunoprecipitates (IP) were evaluated with antibody to phosphoty-
rosine (P-Tyr), IGF-1R (13-subunit), or IRS-1. The arrow denotes the
13-subunit of the IGF-1R (110 kDa). The bracket identifies the range
of IRS-1 mobility (160-170 kDa) over time. The 160-kDa P-Tyr band
that apparently coimmunoprecipitated with IGF-1R 13-subunit has not
been identified and is not immunoreactive with anti-IRS-1 antibody.
MW, molecular weight markers.
IGF-1R or IRS-1 within the time period (0-12 hr) examined
(data not shown). The hormone-induced decrease in the gel
mobility of IRS-1 from uterine extracts, as demonstrated in
Fig. 3, was time-dependent. When compared with IRS-1 from
extracts collected at 0 hr (-160 kDa), the mobility of this
protein by 6 hr after E2 was slightly decreased (-170 kDa); by
30 hr, the mobility of IRS-1 was similar to that observed in
control (0 hr) samples (Fig. 4B). Estrogen-dependent changes
in the gel mobility of liver IRS-1 were not detected (data not
shown). At each period examined, IGF-1R and IRS-1 protein
levels in uterine (Fig. 4 A and B) and liver (data not shown)
extracts were not significantly altered by treatment with E2. In
contrast to estrogen treatment, the P-Tyr content of the
uterine IGF-1R and IRS-1 was not enhanced by progesterone,
dexamethasone, or 5a-dihydrotestosterone within the time
period examined (data not shown).
Immunolocalization of P-Tyr and IRS-1 in Uterine Epithe-
lial Cells. Immunoreactive P-Tyr and IRS-1 were examined in
sections of uteri from CD-1 castrates following treatment with
E2 or vehicle to identify cell populations that contain com-
ponents of the estrogen-activated IGF-1R pathway. Prior to
hormone exposure, immunolocalization with anti-P-Tyr anti-
body revealed weak, variable staining among luminal and
glandular epithelial cells; stromal and myometrial cells were
negative (Fig. SA). By contrast, sections from hormone-treated
mice exhibited intense staining in most of the luminal and
glandular epithelial cells; the stromal cells showed weak to
moderate staining (Fig. SB). Though IRS-1 immunoreactivity
was weakly detectable in the.epithelium of control mice (data
not shown), the cytoplasm of nearly all luminal (Fig. SC) and
glandular (data not,shown) epithelial cells exhibited strong
IRS-1 immunoreactivity at 6 hr following treatment with E2.
Stromal staining was not apparent in the estrogen-treated
group (Fig. SC). Staining was negligible in the epithelium and
stroma of the uteri from mice treated with E2 or vehicle when
control rabbit IgG was substituted for primary antibody (data
not shown).
DISCUSSION
In the reproductive tract, the interaction between the stroma
and epithelium is crucial in mediating the biological response
to steroid hormones (reviewed in ref. 24). On this basis, we felt
it was critical in this study to use the whole animal to accurately
assess what receptor tyrosine kinases are activated by estro-
gens. We evaluated the E2-dependent activation of various
receptor tyrosine kinases in the adult mouse uterus to eluci-
date growth factor signaling pathways associated with the
uterotropic response to estrogens. The IGF-1R pathway was
activated by E2 in the mouse uterus as indicated by hormone-
induced tyrosine phosphorylation of the IGF-1R and IRS-1.
The IRS-1 was apparently equivalent to the 170-kDa P-Tyr
band in the extract from hormone-treated mice. The uterine
extracts contained additional E2-enhanced, P-Tyr bands
(p180, p120-130, and p76), suggesting that other receptor
tyrosine kinases and/or substrates are activated following
estrogen exposure. As with p170 (IRS-1), one or more of these
proteins may be part of the IGF-1R signaling cascade. Other
receptor systems, including the receptors for growth hormone
and various cytokines, can also engage IRS-1 (16) implying
that hormonal stimulation of uterine IRS-1 P-Tyr content may
be mediated, at least in part, independently of the IGF-1R.
However, in this study IGF-1R and IRS-1 demonstrate coor-
dinated increases in phosphorylation following E2 treatment,
suggesting that the uterine IGF-1R kinase phosphorylates
IRS-1.
The immunoreactive EGFR, PDGFR (a- and 3-subunits),
and fibroblast growth factor type 2 receptor that were iden-
tified in uterine extracts did not exhibit an increase in P-Tyr
content by 12 hr following treatment with E2, indicating that
these receptor tyrosine kinases are apparently not activated
upon estrogen exposure within the time period investigated.
Stimulation of tyrosine phosphorylation of the EGFR after
EGF exposure was detected in the absence or presence of
estrogen, demonstrating that an activated receptor tyrosine
kinase can be recovered given the present experimental con-
ditions. Because E2 stimulates the uterine synthesis of EGF
(11), transforming growth factor a (12), and PDGF (6), these
growth factor pathways may play roles distinct from IGF-1 in
normal uterine physiology that is not manifested by the
present experimental model, such as the implantation of the
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FIG. 5. Uterine epithelial cells contain immunoreactive P-Tyr and
IRS-1. Estradiol (1 ,tg) or vehicle was administered to ovariectomized
mice. After 6 hr, immunolocalization of P-Tyr or IRS-1 was determined
on trypsinized paraffin sections of perfusion-fixed uteri by the double
peroxidase-antiperoxidase technique. (A) In control animals, P-Tyr im-
munostaining was weak and variable among the luminal (le) and glan-
dular (ge) epithelial cells; stromal (s) and myometrial (m) cells were
negative. L, lumen. (Bar = 100 ,um.) (B) Estrogen-treated mice exhibited
intense P-Tyr immunoreactivity in virtually all luminal epithelial cells and
most glandular epithelial cells; the majority of stromal cells showed weak
to moderate staining. (Bar = 100 ,um.) (C) Following treatment with E2,
IRS-1 immunoreactivity was prominent in the cytoplasm of nearly all
luminal epithelial cells; stromal staining was not evident. (Bar = 20 ,tm.)
IRS-1 immunoreactivity appeared weaker in epithelial cells of control
mice (data not shown) than in hormone-treated mice. This was not due
to changes in protein level per se, since E2 did not apparently increase
uterine IRS-1 levels as observed with immunoblots (see Fig. 4B).
Stimulation of tyrosine phosphorylation of the uterine
IGF-1R and IRS-1 following hormone exposure is compatible
with E2-enhanced transcription of the IGF-1 gene in the
uterus of several species, including the rat (13), mouse (27),
and monkey (28). In the hypophysectomized, ovariectomized
rat, it was shown that uterine, but not hepatic or renal, IGF-1
mRNA was increased by 3 hr after E2 treatment (13). Our
findings in mice extend these data by demonstrating that E2
stimulates the P-Tyr content of the IGF-1R and IRS-1 in the
uterus, but not in the liver, by 6 hr following hormone
exposure. The rapid stimulation of uterine IGF-1 mRNA
abundance by E2 (13) coincides with the observations that de
novo protein synthesis is not required for estrogen-induction of
IGF-1 transcription in the rat uterus (29) or in primary cultures
of osteoblastic cells (30).
The immunolocalization of P-Tyr and IRS-1 in the uterine
epithelium following E2 exposure and the estrogen-specific
tyrosine phosphorylation of the IGF-1R and IRS-1 suggest
that the IGF-1-activated signaling cascade plays a role in
E2-induced mitogenesis. Hormonal activation of the IGF-1R
pathway was observed prior to the initial increase of DNA
synthesis (-8 hr) observed in mouse luminal epithelial cells
following E2 exposure (1). The propagation of hormone-
stimulated, tyrosine phosphorylated IGF-1R and IRS-1 in the
uterus may be important for the continued progression of the
epithelial cells into the S phase of the cell cycle (31). Reduction
of uterine weight following treatment with the estrogen an-
tagonist ICI 182,780 was associated with inhibition of uterine
IGF-1 gene expression, suggesting that the local expression of
this gene is an important determinant of uterine growth (32).
Recently, it was reported that E2-enhanced uterine epithelial
DNA synthesis was significantly decreased in castrated mice
overexpressing rat insulin-like growth factor binding protein-1
in the uterine epithelium, as compared with that for wild-type
mice, providing additional evidence that IGF-1 is an important
mediator of E2-induced proliferation in this tissue (33). In
addition to mitogenesis, IGF-1 stimulates progesterone recep-
tor levels in rat uterine cells in culture (34), suggesting that this
growth factor mediates multiple activities in the uterus. Since
tyrosine phosphorylated IRS-1 provides binding motifs for
SH2-containing proteins, such as Grb2 (35, 36) and PTP1D
(37), this docking protein may couple the IGF-1-stimulated
IGF-1R to multiple signaling pathways, including the mito-
genic pathway (38). Alternate signaling pathways regulating
IGF-1-induced cellular proliferation may exist, such as the
engagement of the IGF-1R with Shc (38, 39). Identification of
the intracellular proteins that are recruited to the uterine
IGF-1R/IRS-1 following E2 stimulation will be crucial in
defining the hormone-induced signaling pathways that elicit
proliferation in this target tissue.
In this study, P-Tyr and a component of the IGF-1R pathway
were observed in the uterine epithelium following treatment
with E2, suggesting that the tyrosine phosphorylations ob-
served in response to estrogen are reflecting, for the most part,
hormonal action on the epithelium. Hormone-induced DNA
synthesis in the estrogen-receptor devoid epithelium of the
neonatal mouse uterus (40) and reexpression of estrogen-
dependent proliferation by mouse uterine epithelial cells when
recombined with homologous stroma and transplanted in vivo
(41) suggest that the proliferative response of the epithelium
is mediated by factors produced by the estrogen receptor-
positive stroma in response to estrogens. These data and
previous studies (3) suggest that IGF-1 may be one of these
paracrine factors that mediates E2-induced uterine epithelial
proliferation through activation of the IGF-1R and IRS-1 in
the epithelium. Tissue recombination experiments with uteri
from mature, estrogen receptor null mice (42) and wild-type
littermates provide further evidence that the estrogen receptor
in the stroma, but not in the epithelium, is required for
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In summary, we show for the first time, to the best of our
knowledge, that E2 stimulates tyrosine phosphorylation of the
IGF-1R and IRS-1 in the mouse uterus. Hormonal activation
of IRS-1 is epithelial, estrogen-specific, and is initiated well
before maximal epithelial DNA synthesis (-16 hr) occurs
following treatment with hormone, indicating that this protein
probably has a pivotal role in the transduction of the hormonal
signal for mitogenesis in the mouse uterus. We propose that
IRS-1 becomes engaged in the proliferative pathway of the
uterine epithelium after estrogen stimulation of IGF-1 syn-
thesis in proximal stromal cells, which, in a paracrine manner,
activates the IGF-I receptor kinase in epithelial cells, leading
to IRS-1 phosphorylation and subsequent signal coupling.
Experiments with intact mice carrying null mutations of the
genes encoding IGF-I (43-45) or IRS-1 (46, 47) should be
informative in relating the IGF-1/IGF-lR pathway to E2-
induced proliferation and determining the importance of
IGF-1 in stimulating other unknown receptor tyrosine kinases
or downstream targets following hormone exposure.
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